Dopaminergic Neuronal loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Ramonet, David ^a   Daher, João Paulo L ^b,c   Lin, Brian M ^b   Stafa, Klodjan ^a   Kim, Jaekwang ^b,d   Banerjee, Rebecca ^e   Westerlund, Marie ^f   Pletnikova, Olga ^b   Glauser, Liliane ^a   Yang, Lichuan ^e   Liu, Ying ^b   Swing, Deborah A ^h   Beal, M Flint ^e   Troncoso, Juan C ^b   McCaffery, J Michael ^g   Jenkins, Nancy A ^h,i   Copeland, Neal G ^h,i   Galter, Dagmar ^f   Thomas, Bobby ^e   Lee, Michael K ^b,d   Dawson, Ted M ^b   Dawson, Valina L ^b   Moore, Darren J ^a   more..

^a EPFL   (Switzerland)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f KAROLINSKA INSTITUTE   (Sweden)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; DOPAMINE; LRRK2 PROTEIN, HUMAN; MUTANT PROTEIN; PROTEIN SERINE THREONINE KINASE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CELL LOSS; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; GENE MUTATION; MOUSE; NERVE CELL DEGENERATION; NEURITE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PATHOGENESIS; TRANSGENIC MOUSE; AMINO ACID SUBSTITUTION; ANIMAL; ANIMAL BEHAVIOR; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MESENCEPHALON; METABOLISM; MOTOR ACTIVITY; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PROTEIN TRANSPORT; ULTRASTRUCTURE;

MUS; MUS MUSCULUS;

AMINO ACID SUBSTITUTION; ANIMALS; AUTOPHAGY; BEHAVIOR, ANIMAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; HUMANS; MESENCEPHALON; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MUTANT PROTEINS; NEURITES; ORGAN CULTURE TECHNIQUES; PROTEIN TRANSPORT; PROTEIN-SERINE-THREONINE KINASES;

EID: 79953758383     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018568     Document Type: Article

References (61)

1. Gasser T, (2009) Mendelian forms of Parkinson's disease. Biochim Biophys Acta 1792: 587-596.
2. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595-600.
3. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-607.
4. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, et al. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 7: 583-590.
5. Moore DJ, (2008) The biology and pathobiology of LRRK2: implications for Parkinson's disease. Parkinsonism Relat Disord 14: S92-98.
6. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, et al. (2005) A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365: 415-416.
7. Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 354: 422-423.
8. Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, et al. (2005) Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365: 410-412.
9. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 354: 424-425.
10. Haugarvoll K, Wszolek ZK, (2006) PARK8 LRRK2 parkinsonism. Curr Neurol Neurosci Rep 6: 287-294.
11. Greggio E, Cookson MR, (2009) Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 1: e00002.
12. Marin I, (2006) The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol Biol Evol 23: 2423-2433.
13. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23: 329-341.
14. Ito G, Okai T, Fujino G, Takeda K, Ichijo H, et al. (2007) GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46: 1380-1388.
15. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, et al. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405: 307-317.
16. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, et al. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 357: 668-671.
17. Li X, Tan YC, Poulose S, Olanow CW, Huang XY, et al. (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 103: 238-247.
18. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, et al. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102: 16842-16847.
19. West AB, Moore DJ, Choi C, Andrabi SA, Li X, et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16: 223-232.
20. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, et al. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52: 587-593.
21. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, et al. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9: 1231-1233.
22. Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, et al. (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A 102: 18676-18681.
23. Plowey ED, Cherra SJ 3rd, Liu YJ, Chu CT, (2008) Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem 105: 1048-1056.
24. Saha S, Guillily MD, Ferree A, Lanceta J, Chan D, et al. (2009) LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J Neurosci 29: 9210-9218.
25. Sakaguchi-Nakashima A, Meir JY, Jin Y, Matsumoto K, Hisamoto N, (2007) LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr Biol 17: 592-598.
26. Wang D, Tang B, Zhao G, Pan Q, Xia K, et al. (2008) Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Mol Neurodegener 3: 3.
27. Andres-Mateos E, Mejias R, Sasaki M, Li X, Lin BM, et al. (2009) Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). J Neurosci 29: 15846-15850.
28. Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R, et al. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 107: 9879-9884.
29. Liu Z, Wang X, Yu Y, Li X, Wang T, et al. (2008) A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A 105: 2693-2698.
30. Ng CH, Mok SZ, Koh C, Ouyang X, Fivaz ML, et al. (2009) Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci 29: 11257-11262.
31. Li X, Patel JC, Wang J, Avshalumov MV, Nicholson C, et al. (2010) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci 30: 1788-1797.
32. Li Y, Liu W, Oo TF, Wang L, Tang Y, et al. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 12: 826-828.
33. Lin X, Parisiadou L, Gu XL, Wang L, Shim H, et al. (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 64: 807-827.
34. Melrose HL, Daechsel JC, Behrouz B, Lincoln SJ, Yue M, et al. (2010) Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 40: 503-517.
35. Tong Y, Pisani A, Martella G, Karouani M, Yamaguchi H, et al. (2009) R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A 106: 14622-14627.
36. Liu BH, Wang X, Ma YX, Wang S, (2004) CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression. Gene Ther 11: 52-60.
37. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, et al. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287: 1265-1269.
38. Wang CY, Guo HY, Lim TM, Ng YK, Neo HP, et al. (2005) Improved neuronal transgene expression from an AAV-2 vector with a hybrid CMV enhancer/PDGF-beta promoter. J Gene Med 7: 945-955.
39. Geyer MA, (2006) The family of sensorimotor gating disorders: comorbidities or diagnostic overlaps? Neurotox Res 10: 211-220.
40. Parisiadou L, Xie C, Cho HJ, Lin X, Gu XL, et al. (2009) Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci 29: 13971-13980.
41. Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, et al. (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57: 918-921.
42. Lee BD, Shin JH, VanKampen J, Petrucelli L, West AB, et al. (2010) Inhibitors of leucine-rich repeast kinase-2 protect against models of Parkinson's disease. Nat Med 16: 998-1000.
43. Dusonchet J, Kochubey O, Stafa K, Young SM, Zufferey R, et al. (2010) A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J Neurosci 31: 907-912.
44. Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, et al. (2006) Biochemical and pathological characterization of Lrrk2. Ann Neurol 59: 315-322.
45. Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, et al. (2006) Lrrk2 and Lewy body disease. Ann Neurol 59: 388-393.
46. Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, et al. (2009) LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 18: 4022-4034.
47. Xiong Y, Coombes CE, Kilaru A, Li X, Gitler AD, et al. (2010) GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet 6: e1000902.
48. Wang L, Xie C, Greggio E, Parisiadou L, Shim H, et al. (2008) The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 28: 3384-3391.
49. Moore DJ, Dawson TM, (2008) Value of genetic models in understanding the cause and mechanisms of Parkinson's disease. Curr Neurol Neurosci Rep 8: 288-296.
50. Galter D, Westerlund M, Carmine A, Lindqvist E, Sydow O, et al. (2006) LRRK2 expression linked to dopamine-innervated areas. Ann Neurol 59: 714-719.
51. Westerlund M, Belin AC, Anvret A, Bickford P, Olson L, et al. (2008) Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: Implications for Parkinson's disease. Neuroscience 152: 429-436.
52. Moore DJ, West AB, Dikeman DA, Dawson VL, Dawson TM, (2008) Parkin mediates the degradation-independent ubiquitination of Hsp70. J Neurochem 105: 1806-1819.
53. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, et al. (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60: 557-569.
54. Higashi S, Biskup S, West AB, Trinkaus D, Dawson VL, et al. (2007) Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res 1155: 208-219.
55. Daher JP, Ying M, Banerjee R, McDonald RS, Hahn MD, et al. (2009) Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. Mol Neurodegener 4: 34.
56. West MJ, (1993) New stereological methods for counting neurons. Neurobiol Aging 14: 275-285.
57. Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, et al. (2008) Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J Neurosci 28: 13805-13814.
58. McCaffery JM, Farquhar MG, (1995) Localization of GTPases by indirect immunofluorescence and immunoelectron microscopy. Methods Enzymol 257: 259-279.
59. Frezza C, Cipolat S, Martins de Brito O, Micaroni M, Beznoussenko GV, et al. (2006) OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 126: 177-189.
60. Qiu Z, Ghosh A, (2008) A calcium-dependent switch in a CREST-BRG1 complex regulates activity-dependent gene expression. Neuron 60: 775-787.
61. Pletnikov MV, Ayhan Y, Nikolskaia O, Xu Y, Ovanesov MV, et al. (2008) Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatry 13: 173-186, 115.